CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that the German Red Cross in the Baden-Württemberg – Hessen region (DRK BWH), including Frankfurt, has been granted authorization by the Paul Ehrlich Institute (PEI) to market platelet components treated with the INTERCEPT Blood System. The marketing authorization covers platelets collected from single donors by apheresis. A broader marketing authorization covering pooled platelets using the buffy coat method of collection is pending. The DRK BWH is one of the large Red Cross Donor Services in Germany, collecting and processing approximately 25% of the blood supply in Germany.
